Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Tomin Perea-Chamblee"'
Autor:
Marta Galanti, Juan Angel Patiño-Galindo, Ioan Filip, Haruka Morita, Angelica Galianese, Mariam Youssef, Devon Comito, Chanel Ligon, Benjamin Lane, Nelsa Matienzo, Sadiat Ibrahim, Eudosie Tagne, Atinuke Shittu, Oliver Elliott, Tomin Perea-Chamblee, Sanjay Natesan, Daniel Scholes Rosenbloom, Jeffrey Shaman, Raul Rabadan
Publikováno v:
PLoS Biology, Vol 22, Iss 1 (2024)
Externí odkaz:
https://doaj.org/article/c0a1379f188641c093d3f160a651b129
Autor:
Christopher J. Fong, Michele Waters, Karl Pichotta, Justin Jee, Devika R. Jutagir, David Ma, Tomin Perea-Chamblee, Susie Kim, Kanika Arora, Brooke Mastrogiacomo, Thinh Tran, Steven Maron, Mirella Altoe, Anisha Luthra, Joseph Kholodenko, Arfath Patha, Doori Rose, Michael F. Berger, Gregory J. Riely, Nikolaus Schultz, Sanna Goyert, Adam Schoenfeld, Francesca Gany, Jian Carrot-Zhang
Publikováno v:
Cancer Research. 83:4260-4260
Compared with previous standards of care, the use of immune checkpoint inhibitors (ICI) has brought significant improvements in survival and quality of life for lung cancer patients. However, only a small proportion of these patients respond durably.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e8642be73fa8072eb0561b2cc6caea8
https://doi.org/10.1158/1538-7445.am2023-4260
https://doi.org/10.1158/1538-7445.am2023-4260
Autor:
Amin H. Nassar, Elio Adib, Sarah Abou Alaiwi, Talal El Zarif, Stefan Groha, Elie W. Akl, Pier Vitale Nuzzo, Tarek H. Mouhieddine, Tomin Perea-Chamblee, Kodi Taraszka, Habib El-Khoury, Muhieddine Labban, Christopher Fong, Kanika S. Arora, Chris Labaki, Wenxin Xu, Guru Sonpavde, Robert I. Haddad, Kent W. Mouw, Marios Giannakis, F. Stephen Hodi, Noah Zaitlen, Adam J. Schoenfeld, Nikolaus Schultz, Michael F. Berger, Laura E. MacConaill, Guruprasad Ananda, David J. Kwiatkowski, Toni K. Choueiri, Deborah Schrag, Jian Carrot-Zhang, Alexander Gusev
Publikováno v:
Cancer Cell. 40:1161-1172.e5
The immune checkpoint inhibitor (ICI) pembrolizumab is US FDA approved for treatment of solid tumors with high tumor mutational burden (TMB-high; ≥10 variants/Mb). However, the extent to which TMB-high generalizes as an accurate biomarker in divers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5632bfa3cc7547f7b9501ca14bb4f80
https://doi.org/10.1016/j.ccell.2022.08.022
https://doi.org/10.1016/j.ccell.2022.08.022